📊 MXCT Key Takeaways
Is Maxcyte, Inc.. (MXCT) a Good Investment?
MaxCyte demonstrates strong top-line growth (57.6% YoY) and exceptional gross margins (81.2%), indicating viable core economics. However, the company faces severe profitability challenges with negative operating margins of -157% and operating cash burn of $34.4M against only $33M in revenue, creating a critical cash runway issue despite a healthy balance sheet. Without a clear path to operating leverage and positive cash flow, the company faces imminent funding needs or forced restructuring.
MaxCyte shows strong top-line momentum and excellent gross margins, supported by a debt-free balance sheet and ample liquidity. However, heavy operating losses and significant cash burn indicate a long path to profitability and potential financing risk if efficiency does not improve. Watch for operating leverage to emerge as revenue scales before upgrading the outlook.
Why Buy Maxcyte, Inc.. Stock? MXCT Key Strengths
- Strong revenue growth at 57.6% YoY demonstrates market demand and commercial traction
- Excellent gross margins of 81.2% indicate strong product pricing power and cost structure at the core business level
- Solid balance sheet with $171.5M equity, zero long-term debt, and strong liquidity ratios (8.30x current ratio)
- Rapid revenue growth (+57.6% YoY)
- High gross margin (~81%) signaling strong unit economics
- Strong liquidity and no debt (current ratio 8.3x, D/E 0.0x)
MXCT Stock Risks: Maxcyte, Inc.. Investment Risks
- Severe cash burn of $36.2M in free cash flow against $33M revenue creates unsustainable economics and approximately 6-7 months of cash runway at current burn rate
- Operating expenses far exceed revenue generation despite growth, resulting in -$51.9M operating loss and negative returns on equity (-26%) and assets (-22%)
- Pre-profitability biotech company will likely require dilutive capital raise or debt financing to extend runway, with no visible path to near-term profitability
- Sustained operating losses and large FCF burn (-109.5% margin)
- Potential dilution if external financing becomes necessary
- Execution risk in achieving operating leverage (negative ROE/ROA)
Key Metrics to Watch
- Monthly operating cash burn rate and quarterly cash balance to determine liquidity crisis timeline
- Operating expense growth rate relative to revenue acceleration - critical for path to profitability
- Gross profit growth sustainability and any margin compression signals indicating market competition or cost pressures
- Operating margin (OpEx as % of revenue)
- Free cash flow and liquidity runway
Maxcyte, Inc.. (MXCT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.30x current ratio provides a solid financial cushion.
MXCT Profit Margin, ROE & Profitability Analysis
MXCT vs Healthcare Sector: How Maxcyte, Inc.. Compares
How Maxcyte, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Maxcyte, Inc.. Stock Overvalued? MXCT Valuation Analysis 2026
Based on fundamental analysis, Maxcyte, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Maxcyte, Inc.. Balance Sheet: MXCT Debt, Cash & Liquidity
MXCT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Maxcyte, Inc..'s revenue has shown modest growth of 3% over the 5-year period. The most recent EPS of $-0.39 indicates the company is currently unprofitable.
MXCT Revenue Growth, EPS Growth & YoY Performance
MXCT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $4.6M | -$9.4M | $-0.11 |
| Q2 2025 | $5.0M | -$9.4M | $-0.09 |
| Q1 2025 | $5.6M | -$9.5M | N/A |
| Q3 2024 | $4.2M | -$9.4M | $-0.11 |
| Q2 2024 | $5.0M | -$9.4M | $-0.09 |
| Q1 2024 | $5.0M | -$9.5M | N/A |
| Q3 2023 | $4.2M | -$4.1M | $-0.06 |
| Q2 2023 | $5.6M | -$4.1M | $-0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Maxcyte, Inc.. Dividends, Buybacks & Capital Allocation
MXCT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Maxcyte, Inc.. (CIK: 0001287098)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MXCT
What is the AI rating for MXCT?
Maxcyte, Inc.. (MXCT) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MXCT's key strengths?
Claude: Strong revenue growth at 57.6% YoY demonstrates market demand and commercial traction. Excellent gross margins of 81.2% indicate strong product pricing power and cost structure at the core business level. ChatGPT: Rapid revenue growth (+57.6% YoY). High gross margin (~81%) signaling strong unit economics.
What are the risks of investing in MXCT?
Claude: Severe cash burn of $36.2M in free cash flow against $33M revenue creates unsustainable economics and approximately 6-7 months of cash runway at current burn rate. Operating expenses far exceed revenue generation despite growth, resulting in -$51.9M operating loss and negative returns on equity (-26%) and assets (-22%). ChatGPT: Sustained operating losses and large FCF burn (-109.5% margin). Potential dilution if external financing becomes necessary.
What is MXCT's revenue and growth?
Maxcyte, Inc.. reported revenue of $33.0M.
Does MXCT pay dividends?
Maxcyte, Inc.. does not currently pay dividends.
Where can I find MXCT SEC filings?
Official SEC filings for Maxcyte, Inc.. (CIK: 0001287098) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MXCT's EPS?
Maxcyte, Inc.. has a diluted EPS of $-0.42.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MXCT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Maxcyte, Inc.. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MXCT stock overvalued or undervalued?
Valuation metrics for MXCT: ROE of -26.0% (sector avg: 15%), net margin of -135.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MXCT stock in 2026?
Our dual AI analysis gives Maxcyte, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MXCT's free cash flow?
Maxcyte, Inc..'s operating cash flow is $-34.4M, with capital expenditures of $1.8M. FCF margin is -109.5%.
How does MXCT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -135.1% (avg: 12%), ROE -26.0% (avg: 15%), current ratio 8.30 (avg: 2).